Croda upgraded to as bank sees activist catalyst for turnaround

Barclays has upgraded Croda International PLC to 'overweight' from 'equal weight', citing the potential for activist-driven restructuring following Standard Latitude's 5% stake and an expanded £100 million cost-saving program. The broker set a new price target of 3,100p, implying 16% upside, as Croda's shares have fallen 70% since 2021, reaching what Barclays considers "trough levels." The bank believes risks are now balanced by restructuring opportunities, activist engagement, and stabilizing free cash flow generation, despite concerns over underutilized manufacturing sites and an oversupplied lipid market.

Analysis

Barclays has upgraded Croda International to 'overweight' from 'equal weight', identifying a potential turnaround driven by both internal and external catalysts. The thesis is underpinned by the arrival of activist investor Standard Latitude, which has disclosed a stake of just over 5% and is expected to accelerate portfolio restructuring and improve discipline. Internally, Croda has more than doubled its cost-saving program to £100 million, which Barclays estimates could expand operating margins by up to 400 basis points in a bull case scenario. This upgrade occurs in the context of a 70% share price decline since its 2021 peak, leaving the valuation at what the bank describes as "trough levels." While the new price target of 3,100p is a reduction from a prior 3,600p, it still implies a 16% upside. Persistent headwinds, including underutilised manufacturing sites and an oversupplied lipid market, remain key risks, but Barclays contends these are now balanced by the company's stronger-than-peer gross margins, stabilising free cash flow, and the potential for activist-led improvements.

Key Decisions for Investors

• Investors could consider the activist presence and trough valuation as a compelling entry point, aligning with Barclays' 'overweight' rating and 16% upside target.
• It is critical to monitor the execution of the expanded £100 million cost-saving program and any strategic actions from activist Standard Latitude, as these are the primary catalysts for the potential re-rating.
• Despite the positive catalysts, the noted risks of underutilised assets and an oversupplied lipid market warrant a cautious stance, suggesting investors might await tangible evidence of margin improvement or portfolio changes before building a full position.